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Abstract  
 
 
Background:  
Local cancer relapse rates after breast conservation surgery followed by radiotherapy have 
fallen sharply in many countries with risk influenced by patient age and clinico-pathological 
factors. In women at lower than average risk of local relapse, partial breast radiotherapy 
restricted to the vicinity of the original tumour is hypothesised to improve the balance of 
beneficial versus adverse effects compared with whole breast radiotherapy.  
 
Methods:  
The IMPORT LOW trial (ISRCTN12852634) recruited women aged ≥50 years after breast 
conserving surgery for invasive ductal adenocarcinoma pT≤3cm, pN0-1, G1-3 and ≥2mm 
resection margins. Using 15 daily treatments, patients were randomly allocated (1:1:1) to 40 Gy 
whole breast radiotherapy (control), 36 Gy whole breast plus 40 Gy to partial breast (reduced 
dose) or 40 Gy partial breast only (partial breast). Primary endpoint was ipsilateral local tumour 
control (80% power to exclude a +2.5% non-inferiority margin at 5 years for each test group).  
Field-in-field intensity modulated radiotherapy was delivered using standard tangential beams 
that were simply reduced in length for the partial breast group. 
 
Findings:  
Between May 2007 and October 2010, 2018 women were recruited (control n=675, reduced 
dose: n=674, partial breast: n=669). With a 72.2 month median follow-up (IQR 61.7-83.2), 5-year 
local relapse rates were 1.1% (95%CI 0.5-2.3), 0.2% (0.02-1.2) and 0.5% (0.2-1.4) in control, 
reduced dose and partial breast groups. Estimated absolute differences in local relapse rate 
compared with the control group were -0.73% (-0.99, 0.22) for the reduced dose and -0.38% (-
0.84, 0.90) for the partial breast groups, demonstrating non-inferiority for both test schedules. 
Photographic, patient and clinical assessments recorded comparable, and in some domains, 
lower, levels of adverse effects after reduced dose or partial breast radiotherapy, including two 
patient domains achieving statistically significantly lower adverse effects compared with whole 
breast radiotherapy. Breast cancer prognosis was excellent with no statistically significant 
difference in rates of distant relapse, disease-free survival and overall survival between 
treatment groups. 
 
Interpretation:  
At 5 years, partial breast and reduced dose radiotherapy achieved local relapse rates non-
inferior to those observed following whole breast radiotherapy in selected patients with early 
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breast cancer and equivalent or milder late normal tissue adverse effects. This simple 
radiotherapy technique is implementable in radiotherapy centres worldwide. 
 
Funding: 
Cancer Research UK (CRUK/06/003).  
Manuscript 
 
Introduction 
 
Breast radiotherapy after breast conserving surgery has been shown to reduce the risk of any 
recurrence by one-half and breast cancer mortality by one-sixth in patients with early breast 
cancer [1]. Whole breast radiotherapy is standard of care in the UK and internationally [2-5]. 
Current treatment guidelines discuss partial breast radiotherapy in selected patients based 
mainly on retrospective and prospective cohort studies after treatment using Mammosite® and 
by mature results of a single relatively small well-conducted randomised trial of interstitial 
brachytherapy [6-10]. 
 
One challenge in treating women with early breast cancer has always been to reduce the 
morbidity of radiotherapy without compromising cure. The rationale for investigating partial 
breast radiotherapy is based on falling local relapse rates reported internationally, and 
recognition that a majority of ipsilateral local relapses occur close to the region of the index 
tumour, the so-called tumour bed [11, 12]. Rapid technical advances in radiotherapy combined 
with accurate localisation of the tumour bed using titanium surgical clips enable more precise 
matching of radiotherapy dose intensity to the spatial variation in local relapse risk. This can now 
be achieved using a linear accelerator [13-15]. The advantages of this approach are predicted to 
be fewer chronic adverse effects given the lower exposure of organs at risk, including breast 
tissue, ribcage, lung and heart, without loss of local tumour control. Many thousands of patients 
are currently under follow-up in randomised studies, but mature (5 years or more) data are 
available for a minority [7, 16-18]. Against this background, we report 5-year results of the first 
phase III trial testing partial breast radiotherapy using a standard external beam technique and 
delivered after complete local tumour excision of low risk early breast cancer. 
 
Methods 
Study design 
IMPORT LOW is a multicentre randomised phase III non-inferiority trial comparing the safety 
and efficacy of standard whole breast radiotherapy using accelerated schedules of 40 Gray (Gy) 
in 15 fractions (f) (control) with two experimental schedules of 36 Gy/15f to the whole breast and 
40 Gy/15f to the partial breast (reduced dose), and 40 Gy/15f to the partial breast only (partial 
breast) [19]. All treatment groups received simple forward-planned intensity-modulated radiation 
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techniques (IMRT) to optimise dose homogeneity.  There were two substudies addressing late 
adverse effects, including photographic assessments of the breast and comprehensive patient 
reported outcomes; centres declared upfront whether they wished to participate in the 
substudies. Within participating centres, all patients approached about IMPORT LOW were 
informed about the substudies, and separate consent was given to main trial and substudies. 
Patients were recruited from the participating sites until planned substudy sample size had been 
obtained. 
 
Participants 
Women who were aged 50 years or older who had breast conserving surgery for unifocal 
invasive adenocarcinoma (excluding invasive carcinoma of classical lobular type), pathological 
tumour size ≤3cm (pT1-2), axillary node negative or 1-3 positive nodes (pN0-1), any grade and 
with minimum microscopic margins of ≥2mm were eligible. Patients were ineligible if they had a 
previous malignancy of any kind (unless non-melanomatous skin cancer), had undergone 
mastectomy, received neoadjuvant chemotherapy or concurrent adjuvant chemo-radiotherapy. 
Primary endocrine therapy was allowed as long as the tumour was less than 3.0cm, all other 
inclusion criteria were met and surgery was carried out. Eligibility criteria were amended twice 
during the trial. Women with grade 3 tumours and/or tumours >2cm were excluded prior to a 
protocol amendment (approved 04/03/2008). A subsequent amendment (approved 07/05/2009) 
allowed inclusion of lymphovascular invasion and patients with 1-3 positive nodes. Falling local 
relapse rates demonstrated within the START trial and other studies, indicated that it was safe to 
broaden the eligibility criteria11. The study was approved by the Oxfordshire Research Ethics 
Committee B (06/Q1605/128). It was sponsored by The Institute of Cancer Research and was 
conducted in accordance with the principles of Good Clinical Practice. All patients provided 
written informed consent. The Institute of Cancer Research Clinical Trials and Statistics Unit 
(ICR-CTSU; London, UK) were responsible for study management and carried out central 
statistical data monitoring and all analyses. The Trial Management Group was responsible for 
day to day running of the trial and was overseen by an Independent Trial Steering Committee 
(TSC) and interim data reviewed confidentially by an Independent Data Monitoring Committee 
(IDMC). Patient advocates were involved at every stage of the trial, from initial study design 
through to preparation of the final manuscript.  
 
Randomisation and masking 
Women were randomly assigned (in a 1:1:1 ratio) to receive conventional whole breast 
radiotherapy or one of the two experimental schedules (reduced dose or partial breast). To 
randomise a patient, centres telephoned ICR-CTSU. Computer-generated random permuted 
blocks (mixed size 6 and 9) were used to stratify patients by radiotherapy treatment centre. 
Treatment allocation was not masked from patients or clinicians.  
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Procedures 
It was strongly recommended to insert surgical clips, but if this was not possible, localisation of 
the tumour bed was achieved using ultrasound, MR or CT imaging [13, 20]. If it was not possible 
to adopt one of the recommended procedures, it was permissible to enter a patient provided the 
clinician was confident that clinical localisation was accurate, for example, if there was an 
obvious palpable tissue deficit (appendix 1). [13, 20] The protocol specified forward-planned 
field-in-field IMRT delivered by standard medial and lateral tangential beams reduced in length 
but not in width. Non-target breast tissue medial and/or lateral to the planning target volume was 
thereby included in the high dose zone (figure 1 for radiotherapy technique for partial breast 
group). Details of contouring and planning are described in the IMPORT LOW Radiotherapy 
Planning Pack (appendix 1), which was used in addition to the clinical protocol (appendix 2) and 
developed in partnership with the UK Radiotherapy Trials Quality Assurance (RTTQA) team. 
Each centre completed an initial questionnaire to establish details of their intended technique. In 
addition, the RTTQA team visited each radiotherapy centre before opening to validate 
independently the technique in use against the information given in the questionnaire. 
Measurements were made across the treatment volume within a purpose-made breast phantom, 
with particular reference to dose homogeneity. All plans together with corresponding computed 
tomography data sets were collected electronically and stored at the RTTQA repository. In 
addition, a subset of approximately 1 in 10 patients identified at randomisation had thermo-
luminescence dosimetry (TLD) measurements, which were also sent to the RTTQA team.  
 
After radiotherapy, patients were scheduled for annual follow up to 10 years. Mammographic 
schedule was according to local practice, which was typically annually for the first 5 years and 
then 3-yearly as part of the national screening programme. Normal tissue effects were assessed 
by clinicians, patients and using photographs. Clinicians assessed breast shrinkage, distortion, 
induration, breast oedema and telangiectasia at 1, 2, 5 and 10 years using a 4-point scale (“not 
at all”, “a little”, “quite a bit” or “very much”), comparing the ipsilateral versus contralateral breast 
where relevant [21]. The year 1 assessment was only required after protocol amendment 
(approved 04/03/2008). Photographs were taken at baseline (post-surgery and pre-
radiotherapy), 2 and 5 years for patients in the photographic substudy [22].  Patients in the 
patient reported outcomes substudy completed the EORTC QLQ-C30 core questionnaire, 
EORTC QLQ-BR23 breast cancer module, Body Image Scale, protocol-specific questions (skin 
appearance changed, overall breast appearance changed, breast smaller, breast harder/firmer 
to touch), Hospital Anxiety and Depression Scale and the EuroQol EQ-5D-3L. These were 
scheduled at baseline (before randomisation), 6 months, 1, 2 and 5 years. Cases of 
symptomatic rib fracture, symptomatic lung fibrosis and ischaemic heart disease were recorded 
at annual follow-up. 
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Outcomes 
The primary outcome measure was local tumour control, defined as the absence of any 
invasive/non-invasive carcinoma in any location in the ipsilateral breast parenchyma or overlying 
skin. This was recorded as “local relapse”. Secondary efficacy outcomes were location of local 
tumour relapse, time to regional relapse (axilla, supraclavicular fossa and internal mammary 
chain), time to distant relapse, disease-free survival (with an event defined as any local, regional 
or distant relapse, contralateral breast cancer or death due to breast cancer), overall survival, 
contralateral breast cancers and other second primary cancers. Secondary outcomes relating to 
late onset normal tissue effects were assessed by patients, photographs and clinicians.  
 
Patient-reported outcomes focused on key items (arm/shoulder and breast) from the BR23 
module and protocol-specific questions that were dichotomised as moderate/marked (“quite a 
bit/very much”) and presented as proportion occurring at five years and time to development of 
first moderate/marked event. Cross-sectional and time-to-event analyses characterise the 
pattern of normal tissue effects over time.  This manuscript reports on selected items from the 
BR23 breast cancer module and protocol-specific questions that correspond to clinician-reported 
assessments. Further analysis of patient reported outcomes will be reported in a separate 
manuscript.  
 
Digital photographs were scored as showing none, mild or marked change in breast appearance 
at 2 and 5 years compared with baseline by 3 observers using a previously described and 
validated consensus method [22]. Observers were blind to treatment allocation but not year of 
follow-up. Clinician-reported late normal tissue effects were also summarised as the proportion 
of patients with moderate/marked (“quite a bit/very much”) events at five years and time to 
development of first moderate/marked event, for each item scored.  
 
Statistical analysis 
The trial was powered to evaluate non-inferiority of the local relapse rate for each of the 
experimental groups compared with the control group.  A 2.5% local relapse rate at 5 years was 
assumed with whole breast radiotherapy and the trial aimed to exclude an increase of greater 
than 2.5% in local relapse rate in either experimental group. This required 645 patients in each 
group to give 80% power with alpha of 2.5% (one-sided) and allowing for 5% loss to follow-up by 
5 years. A target number of events was not stated in the protocol but data maturity was reviewed 
and discussed by the IDMC and TSC. The IDMC considered data to be sufficiently mature once 
form return rates were at least 80% at 5 years.  
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The photographic substudy required 400 patients per group to have >90% power to detect at 
least a 10% difference in change in overall breast appearance for each experimental group 
compared with control (two-sided alpha of 0.025). With 400 patients per group, the patient 
reported outcome substudy had >80% power to detect differences of at least 15% in the 
prevalence of normal tissue effects (two-sided alpha of 0.005 to allow for multiple testing) and 
allowing for 10% attrition (due to death or illness). The same 0.005 threshold for significance 
was used for the clinician reported normal tissue effects.  
 
Survival analysis methods were used to compare efficacy outcomes between the control group 
and experimental schedules with time measured from randomisation. For time to local relapse, 
patients were censored at death or at last follow-up for those who remained event-free.  For 
distant relapse, disease-free and overall survival, patients not experiencing an event were 
censored at last follow-up. Nelson-Aalen cumulative hazard functions were plotted by treatment 
group. 
 
Kaplan-Meier methods were used to estimate event rates at 5 years with 95% confidence 
intervals (CI). Estimates of treatment effect were made using unadjusted Cox regression 
models, with hazard ratios (HR) <1 indicating a decreased risk of the event in the experimental 
group compared with the control group. Absolute treatment differences in local relapse rate were 
calculated based on the Kaplan Meier estimate of the local relapse-free rate in the control group 
and the HR. Each experimental group could be considered non-inferior to the control group if the 
upper limit of the two-sided 95% CI for local relapse HR was <2.03 (critical hazard ratio, 
excluding an increase in local relapse from 2.5% to 5%). Superiority of each experimental group 
compared to the control could be tested if non-inferiority could be claimed (using a 0.025 
significance level).  Analyses were by intention to treat since compliance to allocated treatment 
was high. The primary outcome was also analysed in the per-protocol population, including all 
patients who completed their protocol-defined radiotherapy regimen, given this was a non-
inferiority trial. 
 
The proportion of late moderate/marked events at five years is reported for each clinician and 
patient-reported late normal tissue event. Fisher’s Exact tests were used to compare each 
experimental schedule with the control group. Time to first moderate/marked event was 
analysed using the Kaplan-Meier method. Patients not experiencing an event were censored at 
last assessment of normal tissues (by clinician or patient as appropriate) or death. For the 
patient reported outcomes, the Cox model was adjusted for baseline scores. Photographic data 
is presented as the proportion of patients with none or mild/marked change in breast 
appearance at 2 and 5 years compared with baseline. The Fisher’s Exact test was used to 
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compare each experimental schedule with the control group at both time points. There was no 
imputation of missing normal tissue data. 
 
For all time-to-event analyses the proportional hazards assumption of the Cox model was tested 
using Schoenfeld residuals and found to hold. Analyses were based on a database snapshot 
taken on 15th June 2016, and performed using STATA version 13. This study is registered, 
number ISRCTN12852634. 
 
Role of funding source 
Cancer Research UK provided peer-reviewed approval for the trial but had no other role in study 
design, collection, analysis, interpretation of data, or report writing. The corresponding author 
had full access to all the study data and had final responsibility for the decision to submit for 
publication. CG and JMB also had full access to study data. 
 
Results 
Between May 2007 and October 2010 2018 patients entered the study from 30 UK radiotherapy 
centres (control n=675, reduced dose n=674 and partial breast n=669). Four patients were found 
to be ineligible after randomisation (three patients had lobular carcinoma and one had previous 
renal cell carcinoma) and two patients withdrew consent from any data being used in analysis 
(Figure 2). Seven patients did not receive any radiotherapy and 54 did not receive their allocated 
treatment (Figure 2). Seventy-four percent of patients had surgical clips, 24% used imaging 
(either CT or ultrasound) and 2% used clinical methods alone to localise the tumour bed.  
Demographic and clinical characteristics were well balanced across the three treatment groups 
(Table 1). Chemotherapy was given to 104 (5%) women, 90% (n=1826/2008) had endocrine 
therapy and 2% (n=36/2008) had trastuzumab. 
 
After a median follow-up of 72.2 (IQR 61.7-83.2) months, local relapse had been reported for 18 
patients  whole breast (n=9), reduced dose (n=3) and partial breast (n=6) groups respectively. At 
five years, the local relapse rates were 1.1% (95%CI 0.5-2.3) in those allocated to whole breast, 
0.2% (0.02-1.2) in the reduced dose and 0.5% (0.2-1.4) in the partial breast groups respectively. 
The estimated absolute treatment differences in the local relapse rate compared with whole 
breast radiotherapy at five years was -0.73 (-0.99, 0.22)% for the reduced dose group and -0.38 
(-0.84, 0.90)% for the partial breast group. Since the upper limit of the two-sided 95% confidence 
interval ruled out a >2.5% increase in local relapse risk for each of the test schedules, non-
inferiority can be claimed for both reduced and partial breast radiotherapy. Confirmation of this 
assertion is illustrated by a test against the critical hazard ratio HR>2.03, with p=0.003 and 
p=0.016 for the reduced and partial groups respectively compared with the whole breast 
radiotherapy group (Table 2 and Figure 3). Analyses in the per-protocol population were 
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consistent (p=0.003 and p=0.017 for the reduced dose and partial breast comparisons 
respectively). Local relapses occurred most frequently in patients with at least one high risk 
feature (Appendix 3).  
 
Four regional relapses were reported: (whole breast (n=1), reduced dose (n=1) and partial 
breast (n=2) groups respectively, of which 2 coincided with local relapse and 2 were isolated 
axillary relapses. Rates of distant relapse, disease-free survival and overall survival were similar 
across treatment groups, with low overall event rates and no statistically significant differences 
observed between experimental and control groups. Thirty-two patients developed invasive 
contralateral breast primary cancers (whole breast (n=10), reduced dose (n=11) and partial 
breast (n=11) groups). Non-breast second primary cancers were reported for 96 patients (whole 
breast (n=35), reduced dose (n=37) and partial breast (n=24) groups (Table 3)). Gastrointestinal, 
gynaecological and lung cancers were the most common. All but one (18/19) of the lung cancers 
developed within five years of randomisation and there were similar numbers ipsilateral and 
contralateral to the treated breast (Appendix 4).  
 
A total of 116 patients had died, 26 from breast cancer, 90 from other causes (including 42 from 
second cancers and 9 cardiac-related) and 2 with unknown cause of death with no evidence of 
disease relapse prior to death (Table 3). There were similar numbers of cardiac deaths for 
patients with left and right sided breast cancers (Appendix 5). 
 
In relation to normal tissue effects, at the 5-year assessment, patients generally reported fewer 
moderate/marked events for the protocol-specific questions (skin change, overall breast 
appearance change, breast smaller and harder/firmer to touch) in the partial breast group 
compared with the whole breast group (Table 4), although this reduction was statistically 
significant for change in breast appearance only (p<0.001). Five-year cumulative incidence 
estimates indicated that change in breast appearance was the most common item reported as 
moderate/marked by patients. There was evidence of a significant reduction  in 
moderate/marked events up to 5 years for both the reduced dose and partial breast (HR<1) 
compared with the whole breast group for  breast harder/firmer only (reduced dose p=0.002; 
partial breast p<0.0001). Cumulative incidence rates of breast harder/firmer were much higher 
than the point prevalence at 5 years as they included events reported earlier on in follow-up, 
many of which were likely to be temporary post-surgical effects. The proportion of patients 
reporting arm and shoulder symptoms as moderate/marked at 5 years was low across all groups 
with no evidence of a difference for either experimental schedule compared with the control 
group. Similarly, cumulative incidence estimates indicated similar rates of arm and shoulder 
symptoms between groups 
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A total of 1319 women consented to the photographic substudy and baseline photographs were 
received and assessable for 1222 patients. Two year photographs were assessable in 1000 
women. The most common reasons for photographs not being available were centre 
administrative oversight meaning photographic appointments were not made, patients not 
attending hospital visits and patients withdrawing consent from the substudy. At two years, mild 
or marked changes in breast appearance were observed in 37/332 (11%), 32/335 (10%) and 
31/333 (10%) allocated to whole breast, reduced dose and partial breast radiotherapy 
respectively. At 5 years, photographs were available for 805 women and, compared with the 2-
year results, the proportion of patients with mild or marked changes had increased across all 
groups (whole breast n=60/262 (23%), reduced dose n=59/264 (22%) and partial breast 
n=50/279 (18%)). There was no evidence of a statistically significant difference in the proportion 
of patients experiencing change in breast appearance for either experimental schedule 
compared with whole breast radiotherapy at 2 (reduced dose p=0.527; partial breast p=0.446) or 
5 years (reduced dose p=0.917; partial breast p=0.165).  
 
Clinical assessment of late normal tissue effects at 5 years showed very low levels of 
moderate/marked events across all treatment groups (Table 5). Breast shrinkage had the 
highest prevalence of moderate/marked events (whole breast n=41/452 (9%), reduced dose 
n=37/478 (8%) and partial breast n=33/472 (7%)). Moderate/marked breast oedema was rare at 
5 years (whole breast n=4/446; reduced dose n=2/468; partial breast n=0/468). The cumulative 
incidences also indicated breast shrinkage to be the most common late normal tissue effect.. 
The hazard ratios for all late effects were consistently <1 but there was no evidence of 
statistically significant differences for individual events. Severe late adverse effects were rare. 
There were 4, 8 and 5 confirmed reports of rib fracture, lung fibrosis and ischaemic heart 
disease respectively (Appendix 6).  
 
Discussion 
Our 5 year results confirm that local relapse rates were very low across all trial groups and that 
non-inferiority was demonstrated for both partial breast and reduced dose radiotherapy. Late 
normal tissue effects were also uncommon across all groups and statistically significantly fewer 
in patient reported breast hardness in the partial breast radiotherapy group compared with 
control. This supports our hypothesis that partial breast radiotherapy using a standard radiation 
technique can reduce late toxicity without jeopardising local tumour control. 
 
IMPORT LOW has several novel aspects. Firstly, it is the only phase III trial of partial breast 
radiotherapy to use the same dose-fractionation regimen and radiation technique in both whole 
breast and partial breast radiotherapy group(s). Therefore, differences in treatment outcome can 
be attributed more reliably to differences in radiotherapy volume. The Danish Breast Cancer 
11 
 
Group phase II partial breast radiotherapy trial is similarly designed to have breast volume as the 
only variable, but has a primary endpoint of grade ≥2 breast induration at 3 years (personal 
communication, B Offersen) 
 
Other phase III partial breast radiotherapy trials report a variety of different dose-fractionation 
regimens ranging from a single intraoperative dose to 1-2 weeks of treatment [18, 23, 24]. These 
differences make it challenging to distinguish variations in outcome being due to differences in 
treated volume or to radiation dose-time effects. This is illustrated by the interim results at 3 
years from the RAPID trial that compared 3D conformal partial breast radiotherapy using 38.5 
Gy in 10 fractions over 5 days, with whole breast radiotherapy using 42.5 Gy or 50 Gy in 16 or 
15 fractions respectively with an optional boost. Cosmetic outcome and late normal tissue 
toxicity were worse in the partial breast radiotherapy group, which suggests that dose-time 
effects were the dominant factor over reduced irradiated volume within this study.  Other 
randomised trials using similar dose-fractionation regimens to RAPID have yet to publish mature 
outcome data although early reports suggest limited toxicity. 
 
A second novel aspect is the engagement of patients to produce the most comprehensive 
patient reported outcomes in any published partial breast radiotherapy trial to date. It is obvious 
that the patient’s viewpoint is extremely important, but previous breast radiotherapy trials have 
also demonstrated that patient reported outcomes are very sensitive in distinguishing between 
different dose-fractionation regimens [25]. IMPORT LOW suggests that patient reported 
outcomes are also able to detect a radiotherapy volume effect. This observation is highly 
relevant for the design of future breast radiotherapy trials as patient reported outcomes could 
prove to be the most cost-effective yet sensitive and patient-centred method of outcome 
assessment. We have analysed and presented the late normal tissue toxicity for both patient 
reported outcomes and clinician reported outcomes in two ways: using discrete 5 year time 
points and also the cumulative incidence. The purpose of dual analysis is to convey different 
information, in that the longitudinal results capture the maximum grades of toxicity, whereas the 
cross sectional 5 year results take into account resolution of some side effects, such as oedema 
that may reduce over time. We acknowledge that multiple statistical tests were conducted for the 
normal tissue toxicity analysis, but we accounted for this by using a stringent significance level of 
0.005 for clinical and patient reported outcomes. 
 
A third important strength of IMPORT LOW is its simplicity. The partial breast radiotherapy 
technique uses standard tangential fields that are simply shortened to encompass the tumour 
bed and margin of healthy tissue. This means that a larger volume of breast is treated in 
comparison with other 3D conformal/IMRT and brachytherapy techniques, but tangential beams 
minimise dose to surrounding organs at risk such as the heart and lungs by keeping the exit 
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beams within the breast. This may be important in minimising second radiation-induced cancers. 
It may also minimise the mean heart dose without the need for breath-hold in most left-sided 
breast cancer patients, given that the majority of patients have tumours in the upper half of the 
breast and above the level of the heart [26] [[27]. The tangential field arrangement is more likely 
to deliver at least some dose to the lower axilla in comparison with more conformal partial breast 
radiotherapy techniques. This may prove to be important in minimising axillary recurrences [28]. 
A simple form of forward planned IMRT was used to optimise dose homogeneity, but this is now 
standard in the vast majority of centres [29, 30]. This means that implementation of this 
technique does not require additional resources or training in the majority of countries.  
 
By today’s standards, the original estimates of local relapse rate on which sample size was 
based were high given recent improvements in outcome [11].  Retrospective power calculations, 
based on year 5 data being available for 1832 (91%) patients and an observed control group 
local relapse rate of 1.1%, confirm that a clinically relevant absolute 2.0% increase in 5-year 
local relapse rate could be excluded for each test group, assuming 80% power and 2.5% alpha 
(one-sided). The demonstration of non-inferiority is expected to be stable with increasing follow-
up, although the local relapse rate in IMPORT LOW is likely to be in the range 1-3% by 10 years. 
This expectation is based on the ELIOT trial in which the cumulative incidence of local relapse in 
the intra-operative group rose in an apparently linear fashion between 5 and 9 years [23]. 
Compliance with photographic assessments was not as high as anticipated. However, given the 
relatively low rate of any change in breast appearance at 5 years in the control group (23%), 
retrospective power calculations indicate that there would be 75% power to detect a difference of 
10% (with a 2.5% significance level).  
 
Another possible limitation is bias in late normal tissue toxicity reporting as it is impossible to 
blind patients and clinicians to treatment randomisation. The panel of assessors undertaking 
photographic assessments are however blinded to treatment arm, albeit that photographic 
assessments appear less sensitive to subtle changes in normal-tissue toxicity.  
 
A major question raised by this trial is: which patients should be selected for partial breast 
radiotherapy? IMPORT LOW had relatively permissive eligibility criteria, but it is apparent from 
the baseline characteristics that the majority of women actually recruited had small, low grade, 
ER+, node negative tumours. This may be partly explained by the widening of eligibility criteria 
during recruitment. Appendix 3 shows that despite the proportional lower number of patients with 
higher risk disease, this group contributed 8 out of 18 of the local relapses. However, this 
observation needs to be taken with caution as the overall number of events was very low. The 
UK has taken a pragmatic approach to patient selection for partial breast radiotherapy by 
producing a consensus statement (breast-cancer-uk-consensus-statements), which states that 
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partial breast radiotherapy can be considered for patients ≥50 years, grade 1–2, ≤30 mm, ER+, 
HER2-, N0 with minimum 1 mm radial excision margins for invasive disease. Given the very 
small percentage of node positive patients in IMPORT Low, we support the UK Breast 
Radiotherapy Consensus in not recommending partial breast radiotherapy for this group. 
Consistent with the findings of ACOSOG Z0011, IBSCG 23-01, NCIC MA20, and EORTC 
22922, we recommend that node positive patients receive whole breast radiotherapy as 
standard of care. 
 
A further controversy raised by this and other reported studies, is the definition of ipsilateral 
“local relapse”. For example the IMPORT LOW definition is recurrence of any pre-
invasive/invasive carcinoma in the ipsilateral breast regardless of histology or location of the 
index breast cancer. The GEC-ESTRO trial definition does not take into account location within 
the breast, but does exclude tumours with differing histology and the Cochrane review only 
includes relapses within the index quadrant with the same histology. Clearly, inclusion or 
exclusion of local relapses could make a substantial difference in reported results given the very 
low event rate in this patient group. 
 
Finally, the results of IMPORT LOW are not consistent with the 2016 overview by the Cochrane 
Collaboration based on the published data of phase III trials, 6 of which contributed to analyses 
of local relapses and 4 to analyses of toxicity endpoints [31]. This overview reported inferior 
results for both local relapse and late normal tissue toxicity with partial breast radiotherapy. The 
relatively small number of contemporary partial breast radiotherapy trials included within this 
report may explain these findings [30]. Four other phase II trials testing partial breast 
radiotherapy are yet to report 5-year results: NSAPBP/RTOG, RAPID, SHARE and IRMA. The 
mature results from over 10,000 patients recruited within these important trials will add to the 
literature in due course. 
 
It is clear that we need the results from as yet unpublished partial breast radiotherapy trials, but 
due to the huge heterogeneity in dose-fractionation regimen, radiotherapy technique, irradiated 
volume and inconsistencies in definition of ipsilateral breast tumour recurrence, it may prove 
challenging to interpret these data. A large individual patient data meta-analysis may go some 
way to resolving this potential dilemma and we strongly support this initiative.  
 
We also recognise the importance of investigating possible effects of partial breast radiotherapy 
on development of radiation induced second cancer and major cardiac events. However, this 
research will require thousands of patients followed up for many years before robust conclusions 
can be made and may be best achieved by future interrogation of routine health data. 
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Another approach will be to investigate the biology of local relapse and its relationship to partial 
breast radiotherapy. For example, it is still unclear what constitutes a “true” ipsilateral recurrence 
from an ipsilateral new primary at the molecular level and this requires further investigation.  
 
Conclusion 
At 5 years, partial breast radiotherapy delivered using a simple intensity modulated technique 
achieved non-inferiority in local relapse rates compared with whole breast radiotherapy and 
comparable or reduced late adverse effects. This method of partial breast radiotherapy appears 
safe and effective and could be implemented easily within the majority of radiotherapy centres 
worldwide.  
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Research in context  
Evidence before this study 
A comprehensive literature search using PubMed and Medline was carried out before the trial 
opened and addressed the following (i) identification of all previous pathological and clinical 
breast radiotherapy studies investigating patterns of recurrence within the ipsilateral breast and 
(ii) results of previous partial breast radiotherapy studies. We concluded that existing research 
suggested that the majority of local relapses occur in the vicinity of the original tumour bed and 
that older trials testing partial breast radiotherapy were uninformative due to suboptimal patient 
selection, poor localisation of the tumour and, hence, inaccurate radiotherapy. We hypothesised 
that partial breast radiotherapy using modern methods of radiotherapy planning and treatment 
would be non-inferior in terms of local relapse rates and may have reduced normal tissue toxicity 
in a low risk of relapse population. This formed part of our peer-reviewed funding application for 
the trial. 
 
Added value of this study 
IMPORT LOW is the first phase III trial reporting 5-year outcome data for local relapse and 
adverse effects after partial breast radiotherapy delivered using standard external beam 
radiotherapy techniques, and is the only trial testing the importance of treatment volume 
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unconfounded by radiotherapy dose-time factors. In addition, it is unique by including very 
comprehensive patient reported outcome measures. 
 
At 5 years, partial breast radiotherapy delivered using a simple and standard technique, showed 
no increase in local relapse rates compared with whole breast radiotherapy, and produced 
equivalent or reduced late adverse effects. Follow-up is continuing and 10 year local relapse 
rates and toxicity will be reported. 
 
Implications of all the available evidence 
IMPORT LOW has similar local relapse rates compared with the recently reported GEC-ESTRO 
brachytherapy partial breast radiotherapy trial that also confirmed non-inferiority. Our method of 
partial breast radiotherapy appears safe and effective and a key advantage of the IMPORT LOW 
partial breast technique is its relative simplicity compared with conformal/inverse planned 
intensity modulated radiotherapy or brachytherapy. The use of standard medial and lateral 
tangential beams also minimise the mean heart dose without the need for breath hold in most 
left-sided breast cancer patients, given that the majority of patients have tumours in the upper 
half of the breast and above the level of the heart. Implementation of this technique will not 
require additional resources or training in the majority of countries worldwide. 
 
 
Figure legends 
Figure 1 – Radiotherapy technique for partial breast group 
Figure 2 - CONSORT Flow Chart 
Figure 3 - Cumulative hazard of local relapse by treatment group 
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Figure 1: Radiotherapy technique for partial breast group. Red denotes the partial breast 
planning target volume and blue shows the radiotherapy field arrangements shaped with 
multileaf collimators. See planning pack, appendix 2, for further details. 
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Figure 2 - CONSORT Flow Chart 
 
2018 randomised*
674 allocated to whole breast radiotherapy 
40Gy  in 15 fractions
673 allocated to reduced breast radiotherapy
36Gy in 15 fraction to whole breast and 40Gy in 15 
fractions to tumour bed
669 allocated to partial breast radiotherapy
40Gy in 15 fractions to tumour bed only
674 included in analysis
   
673 included in analysis 669 included in analysis
666 received allocated radiotherapy
8 did not receive allocated radiotherapy
2 technically unsuitable
3 Investigator decision
2 patient choice or withdrawal of consent
1  died prior to treatment 
648 received allocated radiotherapy
25 did not receive allocated radiotherapy
16 technically unsuitable
4 Investigator decision
4 patient choice or withdrawal of consent 
1 lung cancer detected following randomisation
641 received allocated radiotherapy
28 did not receive allocated radiotherapy
      15 technically unsuitable
2 Investigator decision
7 patient choice or withdrawal of consent
2 ineligible (lobular carcinoma)
2 site error, wrong treatment prescribed 
Included in per-
protocol analysis
* 2 patients withdrew consent from any data being used in analysis  
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Figure 3 Cumulative hazard of local relapse by treatment group 
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669 658(1) 653(1) 648(0) 634(1) 567(0) 341(1) 124(1)Partial breast
673 666(0) 659(0) 647(0) 635(0) 574(1) 342(1) 116(1)Reduced dose
674 666(1) 661(1) 650(0) 633(2) 552(3) 320(1) 115(1)Whole breast
Number at risk (events)
0 1 2 3 4 5 6 7
Years since randomisation
Whole breast
Reduced dose
Partial breast
HRreduced: 0.33 (95% CI 0.09-1.20);  
P-value for non-inferiority: Whole breast vs reduced dose = 0.003 
 
HRpartial: 0.65 (95% CI 0.23-1.84); 
P-value for non-inferiority: Whole breast vs partial breast = 0.016 
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Tables 
 
Table 1 Demographic and clinical characteristics at randomisation by treatment group (n=2016*) 
  
Whole 
breast 
Reduced 
dose 
Partial 
breast 
  
N=674 
N (%) 
N=673 
N (%) 
N=669 
N (%) 
Age 
Median (IQR) 62 (57-67) 63 (57-67) 62 (57-67) 
Side of primary    
Left 336 (50) 344 (51) 348 (52) 
Right 
Not known 
338 (50) 
0 
329 (49) 
0 
321 (48) 
0 
Pathological tumour size (cm)    
Median (IQR) 1.2 (0.8-1.5) 1.1 (0.8-1.6) 1.2 (0.8-1.6) 
Not known 0 0 1 
Tumour grade    
1 298 (45) 272 (40) 284 (43) 
2 310 (46) 328 (49) 320 (48) 
3 
Ungradeable 
64 (9) 
2 
73 (11) 
0 
63 (9) 
1 
Not known 0 0 0 
Re-excision                                                           
 Yes 
 
93 (14) 
 
78 (12) 
 
87 (13) 
No 580 (86) 595 (88) 580 (87) 
Not known 1 0 2 
Axillary surgery performed 
Yes 
No 
Not known 
 
672 (99) 
1 (<1) 
1 
 
673 (100) 
0 
0 
 
666 (99) 
1 (<1) 
2 
Pathological node status 
Positive 
Negative 
Not known 
 
24 (4) 
650 (96) 
0 
 
19 (3) 
654 (97) 
0 
 
16 (2) 
653 (98) 
0 
Histological type 
Infiltrating ductal 
Mixed 
Other 
Not known 
578 (86) 
14 (2) 
79 (12) 
3 
581 (86) 
18 (3) 
73 (11) 
1 
563 (85) 
22 (3) 
80 (12) 
4 
Lymphovascular invasion 
Present 
Absent 
Not known 
 
34 (7) 
459 (93) 
181 
 
47 (10) 
445 (90) 
181 
 
35 (7) 
459 (93) 
175 
ER status    
Positive 640 (95) 638 (95) 633 (95) 
Poor
† 32 (5) 34 (5) 34 (5) 
Not known 2 1 2 
PR status    
Positive 400 (81) 393 (82) 380 (80) 
Poor
† 93 (19) 84 (18) 95 (20) 
Not known 181 196 194 
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HER2 status     
Negative  599 (96) 603 (96) 580 (94) 
Positive 23 (4) 25 (4) 34 (6) 
Not known 52 45 55 
Adjuvant therapy received (not mutually exclusive) 
Chemotherapy 
Endocrine therapy 
Trastuzumab 
Not known 
 
29 (4) 
610 (91) 
7 (1) 
1 
 
42 (6) 
614 (91) 
15 (2) 
3 
 
33 (5) 
602 (90) 
14 (2) 
4 
* Two patients withdrew consent for any of their data to be used in analysis  
†
ER/PR poor refers to less than 10% receptor staining 
 
 
 
 
Table 2 Relapse and mortality by treatment group 
 Cumulative 
no. of events 
Cumulative incidence 
by 5 years 
Hazard ratio
1
 (95% CI)  
 
p-value
2 
 n / pts (%)    
Local relapse 
Whole breast 
Reduced dose 
Partial breast 
 
9/674 (1) 
3/673 (1) 
6/669 (1) 
 
1.1 (0.5-2.3) 
0.2 (0.02-1.2) 
0.5 (0.2-1.4) 
 
1 
0.33 (0.09-1.20) 
0.65 (0.23-1.84) 
 
- 
0.077 
0.420 
Local-regional relapse 
Whole breast  
Reduced dose 
Partial breast 
 
9/674 (1) 
3/673 (1) 
8/669 (1) 
 
1.1 (0.5-2.3) 
0.2 (0.02-1.2) 
0.8 (0.3-1.8) 
 
1 
0.33 (0.09-1.21) 
0.88 (0.34-2.27) 
 
 
0.077 
0.761 
Distant relapse 
Whole breast 
Reduced dose 
Partial breast 
 
13/674 (2) 
10/673 (2) 
12/669 (2) 
 
1.4 (0.7-2.6) 
1.5 (0.8-2.8) 
1.6 (0.8-2.9) 
 
1 
0.77 (0.34-1.75) 
0.92 (0.42-2.03) 
 
 
0.525 
0.838 
Any breast cancer-related event 
Whole breast  
Reduced dose 
Partial breast 
 
33/674 (5) 
24/673 (4) 
33/669 (5) 
 
3.7 (2.5-5.4) 
3.4 (2.2-5.1) 
4.0 (2.8-5.9) 
 
1 
0.72 (0.43-1.22) 
1.00 (0.62-1.62) 
 
 
0.223 
0.982 
All-cause mortality 
Whole breast 
Reduced dose 
Partial breast 
 
40/674 (6) 
39/673 (6) 
37/669 (6) 
 
5.0 (3.6-7.0) 
4.1 (2.8-5.9) 
3.7 (2.5-5.4) 
 
1 
0.97 (0.62-1.50) 
0.91 (0.58-1.42) 
 
 
0.883 
0.693 
1 
Hazard ratio <1 favours experimental group 
2 
Log-rank test, for each experimental group compared with whole breast radiotherapy  
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Table 3- Local relapse, second cancers and deaths by treatment group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Two patients with DCIS 
2 
One patient with DCIS 
3 
One patient reported a colorectal second cancer followed by a lung second cancer and is included as both categories 
4 
Other includes adrenal, squamous cell carcinoma of the skin, melanoma, leukaemia and mesothelioma 
5 
Angiosarcoma developed in the treated breast 
6 
One patient with distant relapse prior to death died from mesothelioma 
7 
One patient with distant relapse prior to death died from renal failure 
8 
Two patients with distant relapse prior to death also died from other causes, one sepsis and one was cardiac related 
 
 
 
 Whole 
breast 
N=674 
N (%) 
Reduced 
dose 
N=673 
N (%) 
Partial 
breast 
N=669 
N (%) 
Total 
 
N=2016 
N (%) 
Local relapse 
 
Local relapse within radiotherapy field 
Yes 
No 
Borderline 
Not documented 
9
1 
(1) 
 
 
9 
0 
0 
0 
3
2 
(1) 
 
 
1 
0 
0 
2 
6 (1) 
 
 
4 
0 
1 
1 
18 (1) 
 
 
14 
0 
1 
3 
Contralateral breast second primary 
Invasive 
DCIS 
 
Non-breast second primary 
Colorectal 
Lung 
Gynaecological 
Other
4 
Oesophagus 
Pancreas 
Lymphoma 
Genitourinary 
Head & neck 
Liver 
Cancer of unknown primary 
Peritoneal 
Sarcoma 
12 (2) 
10 
2 
 
35 (5) 
10
3 
11
3 
5 
4 
0 
1 
0 
3 
1 
0 
0 
0 
1 
13 (2) 
11 
2 
 
37 (5) 
7 
4 
8 
3 
3 
2 
2 
1 
2 
2 
0 
2 
1
5 
13 (2) 
 11 
2 
 
24 (3) 
3 
4 
4 
1 
3 
3 
3 
0 
0 
1 
2 
0 
0 
38 (2) 
32 
6 
 
96 (5) 
20 
19 
17 
8 
6 
6 
5 
4 
3 
3 
2 
2 
2 
Deaths 
Cause of death: 
Breast cancer 
Second cancer 
Cardiac 
Other – cerebrovascular accident 
Other – pulmonary embolism 
Other 
Unknown 
40 (6) 
 
9
6 
14 
5 
1 
0 
11 
0 
39 (6) 
 
7
7 
16 
2 
2 
2 
10 
0 
37 (6) 
 
10
8 
12 
2 
1 
0 
10 
2 
116 (6) 
 
26 
42 
9 
4 
2 
31 
2 
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Table 4 Patient assessments of moderate/marked late adverse events 
 
Moderate/marked events Cumulative 
no. of events 
Cumulative 
incidence  by 5
1
 
years 
Hazard ratio  
(95% CI)  
p-value
2 
Proportion with event at 5 
years 
p-value
3 
n / pts 
randomised 
(%) 
 Comparison with whole n / pts (%) Comparison with whole 
Breast appearance changed 
whole  
reduced 
partial 
 
158/411 (38) 
123/433 (28) 
113/421 (27) 
 
47.7 (41.1-54.8) 
36.7 (30.6-43.6) 
35.1 (28.7-42.5) 
 
1 
0.74 (0.54-1.00), p=0.051 
0.64 (0.46-0.89), p=0.007 
 
80/295 (27) 
66/325 (20) 
49/331 (15) 
 
 
0.047 
<0.0001 
Breast smaller 
whole 
reduced 
partial 
 
119/411 (29) 
110/433 (25) 
104/421 (25) 
 
37.3 (30.9-44.4) 
31.9 (26.3-38.4) 
34.7 (27.5-43.0) 
 
1 
0.83 (0.59-1.16), p=0.280 
0.78 (0.54-1.11), p=0.162 
 
66/294 (23) 
63/326 (19) 
56/331 (17)  
 
 
0.373 
0.086 
Breast harder/firmer 
whole 
Reduced 
partial 
 
115/411 (28) 
74/433 (17) 
58/421 (14) 
 
35.3 (28.4-43.3) 
21.0 (16.2-26.9) 
15.3 (12.0-19.5) 
 
1 
0.53 (0.36-0.79), p=0.002 
0.47 (0.32-0.71), p<0.0001 
 
27/292 (9) 
23/325 (7) 
15/330 (5) 
 
 
0.376 
0.024 
Arm/shoulder pain 
whole 
reduced 
partial 
 
98/411 (24) 
104/433 (24) 
97/421 (23) 
 
32.6 (26.3-39.9) 
30.1 (24.7-36.4) 
27.2 (21.9-33.6) 
 
1 
0.94 (0.71-1.25), p=0.678 
0.97 (0.73-1.28), p=0.809 
 
33/297 (11) 
43/329 (13) 
24/331 (7) 
 
 
0.465 
0.097 
Swollen arm/hand 
whole  
reduced 
partial 
 
21/411 (5) 
26/433 (6) 
16/421 (4) 
 
6.2 (4.1-9.5) 
9.8 (6.2-15.3) 
4.4 (2.7-7.3) 
 
1 
1.19 (0.67-2.11), p=0.558 
0.59 (0.30-1.15), p=0.123 
 
5/295 (2) 
15/330 (5) 
2/330 (1) 
 
 
0.066 
0.264 
Difficulty raising arm 
whole 
reduced 
partial 
 
42/411 (10) 
45/433 (10) 
47/421 (11) 
 
13.6 (9.2-19.8) 
14.0 (9.8-19.8) 
13.5 (10.1-18.0) 
 
1 
0.98 (0.64-1.50), p=0.913 
1.08 (0.71-1.64), p=0.726 
 
10/297 (3) 
17/328 (5) 
15/331 (5) 
 
 
0.326 
0.542 
Shoulder stiffness 
whole 
Reduced 
partial 
 
56/411 (14) 
56/433 (13) 
58/421 (14) 
 
19.3 (14.0-26.5) 
19.3 (13.9-26.4) 
15.3 (12.0-19.5) 
 
1 
0.93 (0.64-1.35), p=0.701 
1.06 (0.73-1.54), p=0.756 
 
12/296 (4) 
22/328 (7) 
13/331 (4) 
 
 
0.161 
0.999 
Breast pain      
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whole 
reduced 
partial 
67/411 (16) 
65/433 (15) 
64/421 (15) 
19.1 (14.9-24.3) 
16.9 (12.9-22.1) 
18.2 (14.1-23.4) 
1 
0.96 (0.68-1.35), p=0.812 
0.96 (0.68-1.36), p=0.830 
13/295 (4) 
18/330 (5) 
13/328 (4) 
 
0.584 
0.842 
Breast swollen                       
whole 
reduced 
partial 
 
31/411 (8) 
26/433 (6) 
17/421 (4) 
 
8.1 (5.7-11.3) 
6.8 (4.7-9.9) 
4.7 (2.9-7.6) 
 
1 
0.84 (0.49-1.41), p=0.503 
0.49 (0.27-0.89), p=0.019 
 
1/295 (<1) 
4/329 (1) 
1/328 (<1) 
 
 
0.377 
0.999 
Breast oversensitive 
whole 
reduced 
partial 
 
64/411 (16) 
59/433 (14) 
54/421 (13) 
 
17.2 (13.7-21.5) 
16.5 (12.0-22.4) 
18.3 (13.0-25.5) 
 
1 
0.89 (0.62-1.27), p=0.526 
0.80 (0.55-1.14), p=0.220 
 
9/296 (3) 
16/330 (5) 
13/330 (4) 
 
 
0.308 
0.665 
Skin problems in breast 
whole 
reduced 
partial 
 
50/411 (12) 
42/433 (10) 
35/421 (9) 
 
15.7 (11.1-21.9) 
13.4 (9.2-19.2) 
9.2 (6.7-12.7) 
 
1 
0.78 (0.52-1.18), p=0.237 
0.64 (0.42-0.99), p=0.045 
 
7/296 (2) 
10/328 (3) 
9/330 (3) 
 
 
0.632 
0.806 
Skin appearance changed 
whole 
reduced 
partial 
 
63/411 (15) 
59/433 (14) 
49/421 (12) 
 
21.0 (15.5-27.9) 
17.9 (13.2-24.0) 
14.6 (10.4-20.5) 
 
1 
1.07 (0.68-1.68), p=0.775 
0.87 (0.54-1.40), p=0.569 
 
22/294 (8) 
23/325 (7) 
12/330 (4) 
 
 
0.878 
0.051 
1
 Estimated at 5 years and 3 months; 
2 
Wald test; 
3 
Fisher’s Exact test 
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Table 5 Clinician assessment of moderate/marked late adverse events 
Moderate/marked events Cumulative 
no. of events 
Cumulative 
incidence by 5
1
 
years 
Hazard ratio  
(95% CI)  
p-value
2 
Proportion with event at 5 
years 
p-value
3 
 n / pts 
randomised 
(%) 
 Comparison with whole n / pts (%) Comparison with whole 
Worst NTE 
whole 
reduced 
partial 
 
134/674 (20) 
108/673 (16) 
94/669 (14) 
 
27.6 (22.5-33.6) 
21.1 (17.2-25.7) 
20.0 (15.6-25.4) 
 
1 
0.77 (0.60-0.99), p=0.043 
0.69 (0.53-0.90), p=0.006 
 
60/457 (13) 
48/480 (10) 
49/474 (10) 
 
 
0.152 
0.221 
Breast shrinkage 
whole  
reduced 
partial 
 
79/674 (12) 
70/673 (10) 
61/669 (9) 
 
18.4 (13.7-24.5) 
13.6 (10.6-17.5) 
13.9 (10.1-19.0) 
 
1 
0.86 (0.62-1.18), p=0.345 
0.78 (0.56-1.08), p=0.134 
 
41/452 (9) 
37/478 (8) 
33/472 (7) 
 
 
0.480 
0.276 
Breast induration (index) 
whole 
reduced 
partial 
 
63/674 (9) 
43/673 (6) 
48/669 (7) 
 
12.7 (9.5-16.8) 
8.4 (6.0-11.6) 
10.8 (7.7-15.1) 
 
1 
0.66 (0.45-0.98), p=0.040 
0.77 (0.53-1.12), p=0.165 
 
21/453 (5) 
13/474 (3) 
24/471 (5) 
 
 
0.161 
0.762 
Breast induration (outside index) 
whole 
reduced 
partial 
 
15/674 (2) 
10/673 (2) 
- 
 
2.3 (1.4-3.8) 
2.1 (1.0-4.1) 
- 
 
1 
0.66 (0.30-1.48), p=0.310 
- 
 
2/450 (<1) 
2/464 (<1) 
- 
 
 
>0.999 
- 
Telangiectasia 
whole 
reduced 
partial 
 
8/674 (1) 
8/673 (1) 
5/669 (1) 
 
1.6 (0.8-3.3) 
3.0 (1.3-6.8) 
0.6 (0.2-1.7) 
 
1 
0.96 (0.36-2.57), p=0.976 
0.62 (0.21-1.92), p=0.401 
 
3/445 (1) 
6/468 (1) 
4/465 (1) 
 
 
0.507 
>0.999 
Breast oedema 
whole 
reduced 
partial 
 
24/674 (4) 
18/673 (3) 
11/669 (2) 
 
4.0 (2.6-6.2) 
3.2 (2.0-5.3) 
1.7 (0.9-3.0) 
 
1 
0.74 (0.40-1.37), p=0.338 
0.46 (0.23-0.94), p=0.029 
 
4/446 (1) 
2/468 (<1) 
0/468 (0) 
 
 
0.441 
0.056 
Other radiotherapy related 
whole 
reduced 
partial 
 
11/674 (2) 
9/673 (1) 
6/669 (1) 
 
1.7 (1.0-3.1) 
1.4 (0.7-2.6) 
0.9 (0.4-2.0) 
 
1 
0.81 (0.34-1.97), p=0.646 
0.55 (0.20-1.49), p=0.234 
 
3/457 (<1) 
0/480 (0) 
0/474 (0) 
 
 
0.263 
0.221 
1
 Estimated at 5 years and 3 months; 
2
 Log-rank test; 
3
 Fisher’s Exact test 
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